Corcept Therapeutics (CORT)

$34.64 +0.56 (1.64%)
Market Cap 3.54B
Revenue (ttm) 761.41M
Net Income (ttm) 99.65M
EPS (ttm) N/A
PE Ratio 40.61
Forward PE 113.85
Profit Margin 13.09%
Debt to Equity Ratio 0.00
Volume 3,205,400
Avg Vol 1,870,364
Day's Range N/A - N/A
Shares Out 106.37M
Stochastic %K 62%
Beta 0.29
Analysts Sell
Price Target $65.40

Company Profile

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery....

Industry: Biotechnology
Sector: Healthcare
Phone: 650 327 3270
Address:
101 Redwood Shores Parkway, Redwood City, United States
TILResearch
TILResearch Mar. 21 at 7:17 AM
$CORT deep dive: $761M revenue, 98% gross margins, zero debt, $532M cash on hand. Lost its patent fight with Teva, but prescription volume still grew 37% in 2025 thanks to a specialty pharmacy model that makes generic substitution difficult. The pipeline spans four programs built on 25 years of cortisol modulation research: ovarian cancer (NDA filed, PDUFA July 11), Cushing's syndrome, ALS, and MASH. The company spent $168M pre-building an oncology salesforce ahead of the ovarian cancer decision. At $35/share, the stock trades well below the probability-weighted expected value in the analysis. But the range of outcomes is wide depending on which pipeline bets pay off and how long it takes for generics to penetrate the market. Full breakdown: https://www.theinvestmentlog.com/posts/cort/2026-03-21
0 · Reply
topstockalerts
topstockalerts Mar. 20 at 7:32 PM
Shares of Corcept Therapeutics rose Friday after director G. Leonard Baker Jr. purchased 100,000 common shares. According to a Form 4 filed with the SEC, Baker bought 75,782 shares at an average price of $33.0022 and 24,218 shares at $33.5633 on March 17, raising his direct holdings to 1,146,631 shares. Baker also holds 3,308,303 shares indirectly through a limited partnership and 1,095,262 shares via a trust. Transactions occurred across multiple trades priced between $32.43 and $33.68. Insider buying can signal confidence in a company’s outlook, though it does not guarantee future performance. $CORT
0 · Reply
Nosh
Nosh Mar. 20 at 3:01 PM
$CORT Starter I believe but in here this level. Let’s see could be a quick or longer swing trade. GL.
0 · Reply
notreload_ai
notreload_ai Mar. 19 at 9:45 PM
$CORT director Leonard Baker Jr. purchased 100,000 common shares at ~$33 each in open-market buys. https://notreload.xyz/corcept-director-buys-100k-shares/
0 · Reply
FilingTracker
FilingTracker Mar. 19 at 9:08 PM
$CORT Insider bought the dip: https://www.sec.gov/Archives/edgar/data/1088856/000120171526000007/xslF345X06/form4-03192026_090326.xml
0 · Reply
Quantumup
Quantumup Mar. 19 at 5:02 PM
Barclays reiterated $XERS Overweight; $9, and said: Current Mkt Cap <$1B Feels Punitive Given $4B Peak Sales. $CORT Torrent Pharmaceuticals Limited/Somerset Therapeutics, LLC $AMPH $ZLDPY $NVO TEVA Barclays added:::LOE Concerns Feel Overblown With a breakout year in 2025 (shares +130%), XERS stock has been volatile in 2026 due primarily to 1) Recorlev LOE concerns and 2) macro volatility. While we have less visibility into the macro, we think the LOE concerns are overblown and came away from our Miami conf with increased conviction.
1 · Reply
EingeLTrade
EingeLTrade Mar. 17 at 8:09 PM
$CORT BO that falling channel
0 · Reply
prusio1
prusio1 Mar. 16 at 4:11 PM
$SLS In the meantime, I’m picking up $RXRX options ahead of the FDA’s official minutes coming out in July/August for the May/June meeting. The core question the company put to FDA is basically: ‘Is our Phase 2 data — the 53% polyp reduction — strong enough to defer a Phase 3 for now?’ If the FDA signals yes, Recursion effectively steps into commercial‑stage biotech territory. High‑risk, but the upside justifies the bet. Also keeping an eye on $CORT heading into the July PDUFA. That date is basically judgment day for the entire valuation. Worth taking a position here too. Both names have legitimate triple‑up potential.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 13 at 4:55 PM
$CORT Share Price: $31.98 Contract Selected: Aug 21, 2026 $30 Calls Buy Zone: $6.38 – $7.88 Target Zone: $11.09 – $13.55 Potential Upside: 64% ROI Time to Expiration: 160 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
moorenard1
moorenard1 Mar. 13 at 3:16 PM
$CORT Without drawing any attention to it, in the last six weeks, short sellers have dumped an additional 4.5 million shares of stock (pushing price down from $39 to $34). That's incredible. They sold $175 million worth of stock that they don't own, and were only able to push the stock down $4-$5. What's more important, is that their time to cover has exploded by almost 3 fold! There are now 12.5 million shares short and they are completely exposed! Here are some things to keep in mind when thinking about the upcoming SHORT SQUEEZE: (1) The company has no debt, so there is no possible financial catalyst event on the downside (2) The company is financially robust with over half a billion in cash (3) The company continues to buy back stock, making the short squeeze more and more likely.
0 · Reply
Latest News on CORT
Robbins LLP Urges CORT Stockholders to Contact the Firm for Information About the Class Against Corcept Therapeutics Incorporated

Mar 18, 2026, 5:35 PM EDT - 2 days ago

Robbins LLP Urges CORT Stockholders to Contact the Firm for Information About the Class Against Corcept Therapeutics Incorporated

Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately

Mar 16, 2026, 8:21 AM EDT - 5 days ago

Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately

Corcept Therapeutics Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 11, 2026, 4:48 PM EDT - 10 days ago

Corcept Therapeutics Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026

Mar 10, 2026, 6:00 PM EDT - 10 days ago

REMINDER: Corcept Therapeutics Incorporated Investors With Significant Losses Must Act By April 21, 2026

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Corcept Therapeutics Incorporated Lawsuit - CORT

Mar 10, 2026, 9:00 AM EDT - 11 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Corcept Therapeutics Incorporated Lawsuit - CORT

Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 7:47 PM EST - 24 days ago

Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

Feb 24, 2026, 4:05 PM EST - 25 days ago

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not

Feb 20, 2026, 7:30 AM EST - 4 weeks ago

Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

Feb 19, 2026, 4:00 PM EST - 4 weeks ago

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

Corcept Therapeutics Stock Plunges As Court Clears Teva Generic

Feb 19, 2026, 11:48 AM EST - 4 weeks ago

Corcept Therapeutics Stock Plunges As Court Clears Teva Generic

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call

Feb 17, 2026, 4:05 PM EST - 4 weeks ago

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

Feb 9, 2026, 10:58 AM EST - 5 weeks ago

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT

Feb 9, 2026, 4:54 AM EST - 5 weeks ago

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT

Allspring Emerging Growth Fund Q4 2025 Performance Review

Feb 4, 2026, 2:24 PM EST - 6 weeks ago

Allspring Emerging Growth Fund Q4 2025 Performance Review

AMSC ATI CRS CSTL CVLT CWAN TARS

Corcept Therapeutics (CORT) Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application – Hagens Berman

Feb 4, 2026, 8:42 AM EST - 6 weeks ago

Corcept Therapeutics (CORT) Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application – Hagens Berman

Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing

Jan 30, 2026, 8:32 PM EST - 7 weeks ago

Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing

Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application

Jan 30, 2026, 2:20 PM EST - 7 weeks ago

Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application

Corcept shares tumble after FDA letter reveals warnings before drug rejection

Jan 30, 2026, 10:36 AM EST - 7 weeks ago

Corcept shares tumble after FDA letter reveals warnings before drug rejection

Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses

Jan 30, 2026, 10:13 AM EST - 7 weeks ago

Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses

Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps

Jan 22, 2026, 11:12 AM EST - 2 months ago

Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps

Corcept's cancer drug meets main goal in late-stage trial

Jan 22, 2026, 8:13 AM EST - 2 months ago

Corcept's cancer drug meets main goal in late-stage trial

Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Jan 22, 2026, 8:00 AM EST - 2 months ago

Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

These under-the-radar stocks combine fast growth with big upside potential

Jan 15, 2026, 10:31 AM EST - 2 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CTRE DCOM DOCN ENVA

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT

Jan 14, 2026, 9:52 PM EST - 2 months ago

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – CORT

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman

Jan 14, 2026, 11:56 AM EST - 2 months ago

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman

CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Jan 13, 2026, 9:43 AM EST - 2 months ago

CORT INVESTIGATION: Corcept Therapeutics Investors Should Contact Block & Leviton LLP To Potentially Recover Losses

Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT)

Jan 12, 2026, 12:11 PM EST - 2 months ago

Scott+Scott Attorneys at Law LLP Announces Its Investigation Into Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman

Jan 9, 2026, 3:24 PM EST - 2 months ago

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT)

Jan 9, 2026, 10:00 AM EST - 2 months ago

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT)

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT)

Jan 7, 2026, 2:33 PM EST - 2 months ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A  Viable Drug

Jan 4, 2026, 7:08 AM EST - 2 months ago

Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A  Viable Drug

Why Corcept Therapeutics stock crashed today and what comes next?

Dec 31, 2025, 4:02 PM EST - 2 months ago

Why Corcept Therapeutics stock crashed today and what comes next?

TILResearch
TILResearch Mar. 21 at 7:17 AM
$CORT deep dive: $761M revenue, 98% gross margins, zero debt, $532M cash on hand. Lost its patent fight with Teva, but prescription volume still grew 37% in 2025 thanks to a specialty pharmacy model that makes generic substitution difficult. The pipeline spans four programs built on 25 years of cortisol modulation research: ovarian cancer (NDA filed, PDUFA July 11), Cushing's syndrome, ALS, and MASH. The company spent $168M pre-building an oncology salesforce ahead of the ovarian cancer decision. At $35/share, the stock trades well below the probability-weighted expected value in the analysis. But the range of outcomes is wide depending on which pipeline bets pay off and how long it takes for generics to penetrate the market. Full breakdown: https://www.theinvestmentlog.com/posts/cort/2026-03-21
0 · Reply
topstockalerts
topstockalerts Mar. 20 at 7:32 PM
Shares of Corcept Therapeutics rose Friday after director G. Leonard Baker Jr. purchased 100,000 common shares. According to a Form 4 filed with the SEC, Baker bought 75,782 shares at an average price of $33.0022 and 24,218 shares at $33.5633 on March 17, raising his direct holdings to 1,146,631 shares. Baker also holds 3,308,303 shares indirectly through a limited partnership and 1,095,262 shares via a trust. Transactions occurred across multiple trades priced between $32.43 and $33.68. Insider buying can signal confidence in a company’s outlook, though it does not guarantee future performance. $CORT
0 · Reply
Nosh
Nosh Mar. 20 at 3:01 PM
$CORT Starter I believe but in here this level. Let’s see could be a quick or longer swing trade. GL.
0 · Reply
notreload_ai
notreload_ai Mar. 19 at 9:45 PM
$CORT director Leonard Baker Jr. purchased 100,000 common shares at ~$33 each in open-market buys. https://notreload.xyz/corcept-director-buys-100k-shares/
0 · Reply
FilingTracker
FilingTracker Mar. 19 at 9:08 PM
$CORT Insider bought the dip: https://www.sec.gov/Archives/edgar/data/1088856/000120171526000007/xslF345X06/form4-03192026_090326.xml
0 · Reply
Quantumup
Quantumup Mar. 19 at 5:02 PM
Barclays reiterated $XERS Overweight; $9, and said: Current Mkt Cap <$1B Feels Punitive Given $4B Peak Sales. $CORT Torrent Pharmaceuticals Limited/Somerset Therapeutics, LLC $AMPH $ZLDPY $NVO TEVA Barclays added:::LOE Concerns Feel Overblown With a breakout year in 2025 (shares +130%), XERS stock has been volatile in 2026 due primarily to 1) Recorlev LOE concerns and 2) macro volatility. While we have less visibility into the macro, we think the LOE concerns are overblown and came away from our Miami conf with increased conviction.
1 · Reply
EingeLTrade
EingeLTrade Mar. 17 at 8:09 PM
$CORT BO that falling channel
0 · Reply
prusio1
prusio1 Mar. 16 at 4:11 PM
$SLS In the meantime, I’m picking up $RXRX options ahead of the FDA’s official minutes coming out in July/August for the May/June meeting. The core question the company put to FDA is basically: ‘Is our Phase 2 data — the 53% polyp reduction — strong enough to defer a Phase 3 for now?’ If the FDA signals yes, Recursion effectively steps into commercial‑stage biotech territory. High‑risk, but the upside justifies the bet. Also keeping an eye on $CORT heading into the July PDUFA. That date is basically judgment day for the entire valuation. Worth taking a position here too. Both names have legitimate triple‑up potential.
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 13 at 4:55 PM
$CORT Share Price: $31.98 Contract Selected: Aug 21, 2026 $30 Calls Buy Zone: $6.38 – $7.88 Target Zone: $11.09 – $13.55 Potential Upside: 64% ROI Time to Expiration: 160 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
moorenard1
moorenard1 Mar. 13 at 3:16 PM
$CORT Without drawing any attention to it, in the last six weeks, short sellers have dumped an additional 4.5 million shares of stock (pushing price down from $39 to $34). That's incredible. They sold $175 million worth of stock that they don't own, and were only able to push the stock down $4-$5. What's more important, is that their time to cover has exploded by almost 3 fold! There are now 12.5 million shares short and they are completely exposed! Here are some things to keep in mind when thinking about the upcoming SHORT SQUEEZE: (1) The company has no debt, so there is no possible financial catalyst event on the downside (2) The company is financially robust with over half a billion in cash (3) The company continues to buy back stock, making the short squeeze more and more likely.
0 · Reply
JustTheNut
JustTheNut Mar. 13 at 11:57 AM
$CORT This is a buy in the teens.
1 · Reply
druvaciam
druvaciam Mar. 12 at 2:43 PM
$CORT Falling like a rock
1 · Reply
SuperGreenToday
SuperGreenToday Mar. 11 at 8:15 PM
$CORT Share Price: $33.70 Contract Selected: Aug 21, 2026 $30 Calls Buy Zone: $6.97 – $8.61 Target Zone: $11.13 – $13.61 Potential Upside: 51% ROI Time to Expiration: 162 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
11thestate
11thestate Mar. 11 at 4:35 PM
$CORT is trending for a reason. The deeper we dive, the more shocking it looks — and you'll want to check it out: https://11th.com/cases/corcepttherapeutics-investor-suit
0 · Reply
Estimize
Estimize Mar. 11 at 1:00 PM
Wall St is expecting 0.20 EPS for $CORT Q1 [Reporting 05/06 AMC] http://www.estimize.com/intro/cort?chart=historical&metric_name=eps&utm_co
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Mar. 10 at 8:44 PM
$CORT this could go crazy if that court case is settled going into pdufa
1 · Reply
StokTraitor
StokTraitor Mar. 10 at 7:21 PM
$CORT tomorrow will be worse
1 · Reply
StokTraitor
StokTraitor Mar. 9 at 5:50 PM
$CORT timberrrrrrr
2 · Reply
BioTechHealthX
BioTechHealthX Mar. 8 at 6:53 PM
$CORT Corcept Therapeutics (NASDAQ: CORT) is gaining major attention after analysts highlighted a potential 174% upside fueled by its cancer and endocrine drug pipeline. With an approved therapy already generating revenue and the promising relacorilant program advancing in clinical trials, CORT stock is emerging as a compelling biotech growth story. https://biotechhealthx.com/biotech-news/should-you-now-start-buying-corcept-therapeutics-cort-shares/
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 8 at 4:33 PM
$BEAM $CORT $DYN $LEGN $OLMA Looking for the best biotechnology stocks to buy now? Analysts say these 10 biotech stocks could deliver more than 50% upside as breakthroughs in gene therapy, immuno-oncology, and RNA medicine reshape the healthcare industry. https://biotechhealthx.com/biotech-news/10-best-biotechnology-stocks-to-buy-now-with-more-than-50-upside-potential/
2 · Reply
gucag006
gucag006 Mar. 7 at 9:22 AM
$CORT Understand the dynamics of authorized generic (AG) vs. generic. During Q4/25 ER call, CORT's management mentioned that they have been transitioning their Cushing syndrome customers from branded Korlym to AG. By EOY/25 75% has been converted, and they expect it will settle at 78% by EOY/26. For rare disease drug, according to Gemini AI, the impact on the price is minimum, while the battle ground is the rebates offered to PBBM's and Medicare Part D plans:
1 · Reply
UnoffensiveName
UnoffensiveName Mar. 5 at 8:51 PM
$CORT CONSTANTLY mentioning it
0 · Reply